November 2018
Price: £95 PLUS VAT
Format: DOWNLOADABLE PDF
This seminar will consider the next steps in the development of biosimilars and their role in the NHS - bringing out latest thinking on potential cost saving, developing commissioning frameworks and encouraging uptake, and regulatory issues.
It takes place as the Government analyses feedback from a consultation on legislation to control the costs of branded health medicines - with proposals looking at including biosimilars within the remit of the payment mechanism and price controls.
Delegates will discuss what measures can be taken to encourage the adoption of biosimilars in light of findings from the Cancer Vanguard - as well as the wider impact of the Life Sciences Industrial Strategy in bringing new biological medicines to the market, and encouraging investment in biosimilar exports and manufacturing.
Discussion will also assess the next steps for the regulation of biosimilars and for responding to new entrants in the market - as the seminar follows the recent guidance from the Department of Health and Social Care on what the planned implementation period for Brexit means for the life science sector.
Further sessions will assess what more might be done to support the uptake of biosimilars in the NHS - including priorities for increasing engagement with clinicians, developing local commissioning frameworks and promoting patient choice.
